Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation
Compose a Response to This Article
Other responses
No responses have been published for this article.
